GI CANCERS

Single-dose fosaprepitant dimeglumine (Emend for injection) in combination with antiemetic agents has been approved by the FDA for the preventing

Amitabh Chak, MD, MS, professor of Medicine, director, Clinical Research, Division of Gastroenterolgy Diseases, Case Western Reserve University, discusses advances in esophageal cancer. Chak says some of the more "exciting" developments in the treatment of the disease are transnasal endoscopy, as well as a new type of screening device that acts as a "pap smear" for the esophagus.

Manish A. Shah, MD, a prominent researcher in the gastrointestinal cancer field who is helping to lead the BRIGHTER trial, discussed the ongoing research in an interview with Targeted Oncology.

Manish Shah, MD, Bartlett Family Associate Professor of Medicine, director, Gastrointestinal Oncology Program, Weill Cornell Medical College, discusses doing more than just surgery for patients with locally advanced stomach cancer.

Kenneth Wang, MD, director of the Advanced Endoscopy Group and Esophageal Neoplasia Clinic, Mayo Clinic, discusses his opposition for Barrett's esophagus screening as a preventative measure for esophageal adenocarcinoma.

<div style="color:#003668"><em>"When there is a mismatch between the human genetics and bacterial genetics, this may be one of the factors that leads to gastrointestinal cancer."<p align="right"><span style="color:#747474">- Keith Wilson, MD</span></em></div></p>

In patients with chemotherapy-refractory metastatic colorectal cancer (mCRC), ensituximab (NPC-1C), a chimeric immunoglobulin IgG1 monoclonal antibody, produced stable disease in almost half the patients in a phase II study, without contributing toxicity.

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the role genetic testing for colorectal cancer (CRC) plays in families.

Second-line treatment of metastatic pancreatic cancer proved to be feasible and beneficial, particularly for patients who received nab-paclitaxel in addition to gemcitabine, according to extension data from a phase III trial.

Patients with pancreatic adenocarcinoma enrolled on clinical trials have "profoundly improved survival" compared with patients in the general population, suggesting that oncologists who use trial data to prognosticate may be missing the mark, according to researchers whose work was presented at the 2016 Gastrointestinal Cancers Symposium.

Mismatch repair-deficient gastrointestinal (GI) tumors are highly responsive to checkpoint blockade with anti

Using genomic and proteomic characterization of pancreatic cancer tumors, researchers from Vall d

The safety and efficacy profile of regorafenib in patients with previously treated colorectal cancer (CRC) is similar between US patients and the global study population enrolled in the phase IIIb CONSIGN study, according to Udit Verma, MD, at the 2016 Gastrointestinal Cancers Symposium.

Avelumab, an investigational anti-PD-L1 antibody, showed clinical activity as both a second-line and maintenance therapy in patients, with unresectable gastric or gastroesophageal junction (GEJ) cancer, according to data from a phase Ib presented at the 2016 Gastrointestinal Cancers Symposium.

An orally administered first-in-class cancer stemness inhibitor, BBI608, administered twice daily with weekly paclitaxel has promising activity in patients with refractory, heavily pretreated metastatic pancreatic cancer; particularly in patients who are taxane naive.

Carboplatin/paclitaxel-based chemoradiotherapy (CarPacRT) has sufficient activity to progress into phase II clinical trials as neoadjuvant treatment for patients with resectable esophageal cancer.

Nivolumab (Opdivo) produced an overall response rate (ORR) of 14% with an acceptable safety profile in patients with gastric or gastroesophageal junction (GEJ) cancer, according to data from the phase I/II CheckMate-032 trial.

Combining liposomal irinotecan (nal-IRI; MM-398; Onivyde) with 5-fluorouracil (5-FU) plus leucovorin dropped the risk of death in patients with metastatic pancreatic cancer by 25% following progression on a gemcitabine-based regimen, according to updated data from the phase III NAPOLI-1 trial.

Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy boosted overall survival (OS) and generated fewer adverse events (AEs) compared to standard chemoradiation for patients with locally advanced rectal cancer.

Patients with either gastrointestinal (GI) neuroendocrine tumors (NETs) or NETs of unknown primary origin experienced a 40% or more decrease in their risk of disease progression when treated with everolimus (Afinitor), according to a subanalysis of the phase III RADIANT-4 trial.

Patients with advanced midgut neuroendocrine tumors (NETs) will continue to see major therapeutic benefits from the peptide receptor radionuclide therapy Lu-Dotatate (Lutathera), including an improvement in overall survival and the reduction of progression or death risk by 79%.

Katherine Van Loon, MD, discusses identifying recurrences in gastrointestinal cancers at a point where patients can receive further therapy.

The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

A new study has analyzed intratumoral heterogeneity (ITH) in 12 cancer types and found a "tolerable" level of genomic instability, independent of cancer type, beyond which a cancer may become less aggressive.

The phase III PILLAR trial studying the novel immunotherapy, algenpantucel-L combined with chemotherapy in patients with locally advanced, unresectable pancreatic cancer, has completed enrollment with over 300 patients.